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Abstract
Hematopoietic cell transplantation can cure many high-risk diseases but is associated with 
complexity, cost, and risk. Several areas in transplantation practice were identified in the 2014 
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium (BMT 
CTN SOSS) as high priorities for further study. We developed a survey for hematopoietic cell 
transplantation clinicians to identify current practices in BMT CTN SOSS priority areas and to 
understand, more generally, the variation in approach to transplantation and estimation of 
transplantation benefit in current medical practice. Of 1439 transplantation clinicians surveyed, 
305 responded (20% response rate). Clinicians were well represented by age, experience, 
geography, and size of practice. We found that several techniques identified in the BMT CTN 
SOSS, such as maintenance therapy for acute myeloid leukemia or myelodysplastic syndromes 
after allogeneic transplantation, were already being utilized in practice on and off study, with 
higher rates of use in higher-volume centers. There was significant variation among clinicians in 
use of transplantation technologies and approaches to common transplantation scenarios. 
Appraisals of risks and benefits of transplantation appeared to converge upon similar estimates 
despite the presentation of different hypothetical scenarios. These results suggest overall equipoise 
in several BMT CTN SOSS high-priority areas and support the need for better data to inform 
clinical practice.
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INTRODUCTION
Hematopoietic cell transplantation (HCT) is a life-extending or life-saving therapy for many 
patients with malignant and nonmalignant diseases, but it is 1 of the more costly and 
complex areas of contemporary medical practice [1]. For almost any condition that is 
potentially amenable to transplantation, there are a wide array of management approaches 
that incorporate variations in patient selection criteria, pretransplantation conditioning 
regimens, donor type, graft source, and prevention and management of infectious and 
noninfectious post-transplantation complications. Thus, it is important to subject areas of 
uncertainty or new technology to scientific scrutiny, to identify new standards for the field. 
The 2014 Blood and Marrow Transplant Network (BMT CTN) State of the Science 
symposium (SOSS) identified several areas that were deemed to be high priorities for further 
study [2].
To facilitate the implementation of studies in high-priority areas from the BMT CTN SOSS, 
we sought to determine the extent to which emerging transplantation techniques in these 
areas were already being used in current transplantation practice. Further, by studying 
practice variation, an area highlighted in earlier transplantation studies [3], we hoped to 
better understand the degree to which transplantation clinicians might differ from each 
another in their utilization of new technologies, their preferences for approaches to common 
transplantation problems, and the way in which they estimated the benefits or risks of these 
therapies. As part of this effort, we hoped to find ways to increase the development and 
implementation of research to address areas of practice uncertainty.
We developed a survey to identify current practice patterns and preferences among HCT 
clinicians. Our immediate goal was to inform the BMT CTN about current practices among 
transplantation clinicians in BMT CTN SOSS priority areas to assist future BMT CTN study 
planning. For example, if the survey indicated wide variability in the use of a given 
intervention, that would argue in favor of a study evaluating the utility of that intervention. 
On the other hand, if the survey found broad off-study use of an intervention, that would 
suggest that a study comparing that intervention to a placebo might be difficult to complete. 
Our larger goal was to begin to observe and understand variation in clinicians’ approaches to 
transplantation in contemporary practice. For example, many of the interventions described 
in the BMT CTN SOSS are associated with high costs and potential toxicities, leading to 
their prioritization as topics worthy of study in clinical trials. If our survey found that there 
were high rates of use of these technologies in practice ahead of well-designed clinical trials, 
this would suggest that additional ways to assess benefits and risks of these techniques in 
usual practice are needed. Lastly, by studying treatment preferences among HCT clinicians, 
we hoped to gain insight into the way that decisions are made in usual practice and identify 
potential contributors to practice variation that could be addressed in future work.
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METHODS
Survey Development
A 3-section survey was developed for HCT clinicians. In the first section, 11 questions 
collected participant and practice characteristics, including age, experience, center 
geographic region, and center transplantation volume. A second section of 22 questions 
asked participants to describe their current use, on or off study, of transplantation 
technologies identified within high-priority research areas from the 2014 BMT CTN SOSS. 
Examples included the use of maintenance therapy after allogeneic transplantation for 
FLT3+ acute myeloid leukemia (AML), the use of autologous transplantation for multiple 
sclerosis, and the use of pretransplantation risk stratification variables to guide patient 
selection and decision-making [4-6]. In the third section, questions included 2 hypothetical 
clinical vignettes: 1 about a 45-year-old woman with intermediate-risk AML considering 
transplantation and the other about a 30-year-old male with BCR/ABL-negative B cell acute 
lymphoblastic leukemia (ALL) considering transplantation. Each vignette was associated 
with 7 or 8 questions that asked participants to indicate their treatment recommendation for 
the hypothetical patient or variations of the hypothetical patient (eg, the same patient but a 
different age, or the same patient with a different comorbidity profile) and their estimates of 
long-term success or toxicity of their selected approach. The survey was designed so that 
participants would be asked to answer all questions from the first and second sections and 
then randomized to answer questions from 1 of the 2 vignettes in the third section. The 
survey was pilot tested by 2 of the investigators (W.A.W. and S.J.L.), as well as by 4 
additional transplantation physicians, and revised for clarity. A final copy of the survey is 
attached in the Appendix. Subsequent distribution of the finalized survey to a larger national 
sample of transplantation clinicians was approved by the institutional review board at the 
University of North Carolina. The survey introduction contained the elements of informed 
consent, and completion of the survey indicated consent.
Survey Distribution and Data Collection
The finalized survey was distributed to an electronic mailing list maintained by the Center 
for Blood and Marrow Transplant Research (CIBMTR), using Survey Gizmo 
(www.surveygizmo.com). The intent was to identify practicing transplantation clinicians 
using the CIBMTR mailing list, and the list was reviewed by 1 of the investigators to remove 
participants who were not identified as transplantation clinicians. The final sample size of 
potential participants was 1439. The survey was open from April 24, 2015 through May 26, 
2015. Weekly email reminders were sent to all potential participants, and 2 sequential survey 
drawings ($500 and $250 prizes, respectively) for respondents were held to incentivize 
participation.
Statistical Methods
Statistical analyses were performed using SAS 9.4. Summaries of subject responses to 
survey questions with categorical responses were examined using frequency tables, and 
percentages are reported.
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Exploratory analyses were conducted using Fisher's exact tests, with Monte Carlo estimates 
of the exact P values to compare responses across characteristic categories; unadjusted P 
values are reported.
RESULTS
Participants
Of the 1439 potential participants invited to complete the survey, we received 305 responses. 
Eleven individuals declined to fill out the survey after initially responding. Six participants 
reported spending 0% time on patient care and were excluded from analysis. Fifteen 
participants did not provide information beyond the “general information” section of the 
survey. The overall survey response rate was 20%.
Participant characteristics are described in Table 1. Most participants (86%) were from 
academic centers, with 65% providing care primarily for adult patients. Seventy-seven 
percent of participants had at least 5 years of experience as a transplantation physician, with 
an average of 14.8 years of postfellowship experience per participant. A majority of 
participants (54%) practiced at a BMT CTN core center, and about one-third of participants 
practiced at centers performing a high volume (>100/year) of either autologous or allogeneic 
transplantations.
Maintenance Therapies
Participants were asked whether they recommended various maintenance strategies after 
transplantation for patients in remission. These strategies included FLT inhibitors for FLT3 
internal tandem duplication (ITD)+ AML patients after allogeneic HCT; tyrosine kinase 
inhibitor maintenance therapy for Philadelphia chromosome (Ph)–positive ALL patients 
after allogeneic HCT; antibody-based maintenance therapy for Ph-negative ALL patients 
after allogeneic HCT; hypomethylating agents for myelodysplastic syndrome or AML 
patients after allogeneic HCT; and maintenance therapy such as rituximab, ibrutinib, or 
lenalidomide for diffuse large B cell lymphoma patients after autologous HCT. Figure 1 
depicts the percentage of respondents who would recommend the use of each of these 
approaches, on or off clinical trials. In general, there was already significant uptake of 
maintenance strategies in current practice, though this varied by indication and by the 
willingness of participants to use these strategies outside of existing clinical studies. 
However, of the interventions included in the survey, the only 1 that was recommended for 
use off study by a majority of respondents was the use of tyrosine kinase inhibitor 
maintenance for Ph+ ALL patients after transplantation (72.9%). In contrast, none of the 
other interventions were recommended by a majority for use outside of clinical trials.
Emerging Transplantation Techniques
Respondents were queried about their use of newer transplantation strategies and 
technologies that had been identified as priority areas of study by the 2014 BMT CTN 
SOSS. For example, participants were asked about the use of newer medications in the 
initial management of graft-versus-host disease (GVHD), either instead of corticosteroids 
(low-risk acute GVHD), in addition to corticosteroids (high-risk acute GVHD), or with or 
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without corticosteroids (chronic GVHD) (Figure 2). Although a majority or near majority of 
participants did not use newer medications, several participants indicated that they had used 
a variety of techniques, such as sirolimus alone for low-risk acute GVHD (13.6%), 
extracorporeal photopheresis for high-risk acute GVHD (39.6%), and IL-2 for chronic 
GVHD (11.4%). The use of extracorporeal photopheresis for high-risk acute GVHD on or 
outside of clinical trials was very similar between all center volumes (40.5% for <20 
allogeneic HCT/year, 47.4% for 20 to 50 allogeneic HCT/year, 40.0% for 50 to 100 
allogeneic HCT/year, and 38.3% for >100 allogeneic HCT/year.
Other questions asked about the use of additional transplantation strategies, including 
autologous transplantation for multiple sclerosis, post-transplantation cyclophosphamide for 
GVHD prophylaxis, haploidentical donor natural killer cells for post-transplantation relapse 
prevention, cytomegalovirus-specific T cells for refractory cytomegalovirus infection, and 
screening and prevention strategies for post-transplantation bone density loss. In each 
situation, substantial minorities of participants reported use of these technologies in current 
practice (Table 2). Table 3 demonstrates the use of selected transplantation techniques 
(including a few of the maintenance strategies) categorized by transplantation center volume, 
using the number of allogeneic transplantations performed per year as a surrogate measure 
of volume. Higher-volume centers appeared to be associated with a higher use of newer 
transplantation techniques.
Transplantation Decision-Making
Participants were asked which assessment tools they used to help decide whether to 
recommend transplantation for older adults. Results are shown in Table 4 and Figure 3. The 
HCT-specific comorbidity index (HCT-CI) was used frequently by participants for 
transplantation decision-making (88.5%), whereas other scoring systems of disease risk 
(Disease Risk Index, 36.8%) or overall risk (Pre-Transplant Assessment of Mortality score, 
13.8%) were used less frequently. When categorized by overall center volume (allogeneic 
transplantations per year), participants from higher-volume centers appeared to endorse a 
greater use of nearly all of the instruments available for pretransplantation risk assessment.
Finally, participants were asked to make transplantation recommendations for hypothetical 
patients described in clinical vignettes and to provide estimates of risk associated with their 
preferred management approaches. For each vignette, subsequent questions modified 1 or 
more details of the hypothetical patient and asked participants to reassess decision-making 
and risk. Participants were randomized to answer questions associated with only 1 of the 
vignettes. The first vignette described a 45-year-old female with intermediate-risk AML 
(normal cytogenetics, FLT3 ITD negative, NPM1 negative) who was in remission, had a 
matched sibling donor available, had no major comorbid illnesses, and could perform all of 
her instrumental activities of daily living. In this clinical scenario, the total number of 
respondents was 93. Most respondents recommended a myeloablative conditioning 
allogeneic transplantation (n = 74, 79.6%), though some recommended a reduced-intensity 
transplantation (n = 4, 4.3%) or no transplantation (n = 15, 16.1%) (Figure 4). When asked 
to provide risk estimates associated with their preferred choice, respondents indicated 
similar estimates of treatment-related mortality (TRM) (13% to 19%) regardless of 
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transplantation strategy chosen. Median overall survival estimates at 2 years for those 
recommending transplantation were 61% for those recommending myeloablative 
transplantation and 71% for those recommending reduced-intensity transplantation. 
Participants were then asked what they would recommend if the same hypothetical patient 
had an HCT-CI score of 4, based on diabetes mellitus requiring insulin, forced expiratory 
volume in 1 second of 66% to 80%, and a body mass index of 36. This led to a wider 
distribution of recommended transplantation techniques, with most recommending a 
reduced-intensity transplantation but a sizable minority of participants recommending a 
myeloablative transplantation or no transplantation at all. Toxicity estimates remained 
consistent across recommended strategies, with an estimated TRM of 23% among those 
recommending myeloablative transplantation and 22% for those recommending reduced-
intensity transplantation. When informed that the patient in the original vignette did not have 
a matched sibling or matched unrelated donor identified, the majority of participants (n = 51, 
55%) would recommend no transplantation, whereas fewer participants (n = 42, 45%) would 
recommend a transplantation, with conditioning and donor source preference varying widely 
among those recommending a transplantation, including myeloablative mismatched 
unrelated donor (n = 15), myeloablative haploidentical transplantation (n = 10), 
myeloablative cord blood (n = 9), reduced-intensity mismatched unrelated donor (n= 2), 
reduced-intensity haploidentical (2), and reduced-intensity cord blood (n = 3).
The second vignette described a hypothetical 30-year-old male with standard-risk, Ph-
negative B ALL in first complete remission after “adult-like” induction chemotherapy, 
having no comorbidities and with a matched sibling donor identified. In this clinical 
scenario, the total number of respondents was 89. A majority of participants (n = 61, 68.5%) 
recommended a myeloablative, total body irradiation–based transplantation, though a 
minority of participants recommended a myeloablative, chemotherapy-based transplantation 
(n = 11, 12.4%) or no transplantation at all (n = 17, 19.1%) (Figure 5). Overall survival 
estimates at 2 years were remarkably similar regardless of strategy choice (59% to 62%). 
When the age of the hypothetical patient was changed to 45 from 30, most participants again 
recommended myeloablative total body irradiation–based transplantation, though the 
estimates provided for TRM (20% versus 17%) and overall survival (61% versus 59%) for 
this choice were nearly identical despite the increased age of the hypothetical patient. When 
informed that the patient in the original vignette did not have a matched sibling or matched 
unrelated donor identified, the majority of participants (n = 55, 62%) participants would 
recommend no transplantation, whereas fewer participants (n = 34, 38%) would recommend 
a transplantation, whether from a mismatched unrelated donor (n = 18), haploidentical donor 
(n = 11), or cord blood (n = 5).
DISCUSSION
We surveyed a large group of HCT clinicians in the United States about current 
transplantation practices and preferences and obtained a broadly representative sample of 
individuals from different parts of the country, different size centers, and with varying ages 
and levels of experience. We enriched our questions for topics that were addressed in the 
2014 BMT CTN SOSS, since these topics were felt to represent the future of transplantation 
and potential topics for clinical trials. From our survey results, several themes emerged.
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First, there is a diffusion of new transplantation technology into clinical practice and not 
always within the context of a clinical trial. For example, a majority of survey participants 
expressed a willingness to use tyrosine kinase inhibitors off study. However, far fewer 
favored the use of FLT3 inhibitors or hypomethylating agents off study. Some survey 
participants reported current use of other cutting-edge practices, such as the use of 
autologous transplantation for multiple sclerosis or donor natural killer cells after 
transplantation. In general, it appeared that the use of newer transplantation techniques was 
most prevalent in survey respondents who reported practicing in a large-volume 
transplantation center, suggesting that transplantation center size may be a determinant of 
the diffusion of transplantation innovations, perhaps because they are more likely to have 
clinical trials testing these interventions. We found that center size also appeared to be 
associated with a greater use of risk stratification variables as part of transplantation 
decision-making for older adults. This suggests that the diffusion of pretransplantation 
evaluative processes (and potentially other processes in the peri- or post-transplantation 
periods) may occur in a manner that is similar to the spread of specific transplantation 
technologies.
Interestingly, our results from the hypothetical vignettes showed a consistency around 
outcomes estimation, such as TRM and overall survival, in different treatment scenarios. For 
example, survey respondents reported an average 2-year overall survival estimate of 61% 
and TRM estimate of 19% for a 45-year-old female with intermediate-risk AML receiving a 
myeloablative allogeneic transplantation in first remission. Very similar estimates to the 
above were provided by respondents for overall survival (61%) and TRM (20%) for a 30-
year-old male with standard risk Ph-negative ALL receiving a cyclophosphamide/total body 
irradiation transplantation in first complete remission. There may be a cognitive anchoring 
bias in the way that transplantation physicians estimate the success of their interventions, 
such that estimates of efficacy and toxicity converge around similar numbers, perhaps 
adjusted slightly 1 way or the other for positive or negative risk factors. These estimates may 
or may not correspond with findings from the published literature, such as the Medical 
Research Council trial [7]. It is possible that clinicians are factoring in improvements in 
supportive care and other factors affecting outcomes that have been made since the previous 
studies were published. In any case, despite the consistency in outcomes estimation, there 
was continued variation in the preferences expressed by transplantation clinicians for 
different transplantation techniques. For given scenarios, some respondents recommended 
transplantation and others did not, and some recipients expressed preferences for different 
conditioning intensities and different graft sources. These findings suggest continued 
controversy and lack of consensus in key areas of transplantation practice.
We believe that our findings point to the following strategies that could be used to better 
understand and facilitate optimal practice patterns in the field of HCT.
Clinical Trial Development
As a cooperative trial group dedicated specifically to transplantation, the BMT CTN 
represents a powerful mechanism for addressing key transplantation questions using 
rigorous methodology. In planning BMT CTN studies, however, investigators must 
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recognize that there is variability among physicians concerning their perception of the 
evidence supporting the application of emerging therapies. Indeed, our results demonstrate 
that several techniques proposed at the 2014 BMT CTN SOSS as worthy of investigation are 
already in use at many centers. This creates a risk that studies aimed at evaluating these 
interventions may fail to accrue as planned. On the other hand, it is possible that some 
centers may wish to use an emerging technology in the absence of a concurrent well-
designed clinical trial, but the center may remain willing to enroll onto a clinical trial testing 
this question if 1 is developed. Surveys, such as that presented here, may prove useful in 
clinical trial planning.
A separate issue is whether or not the results of studies alter behavior at centers. For 
example, the BMT CTN 0201 study showed equivalent survival after allogeneic 
transplantation when peripheral blood or bone marrow was used as a source of stem cells, 
with a higher risk of chronic GVHD after peripheral blood stem cell grafts [8]. A subsequent 
analysis confirmed that peripheral blood stem cell grafts were associated with inferior long-
term health-related quality of life and reduced rates of return to work, compared with those 
after bone marrow grafts [9]. Nonetheless, for several reasons, the field had already moved 
towards an increased use of peripheral blood grafts before publication and dissemination of 
the BMT CTN 0201 results, and it is not clear that these results will significantly alter this 
trend [10]. Understanding factors that influence the presence or absence of adoption of BMT 
CTN clinical trials results in usual practice is an important area for further study.
Real-time Registry Use
Transplantation technology evolves sufficiently rapidly that many emerging practices will 
not be formally studied in large randomized clinical trials. At the same time, while local 
innovation has long been an important component of progress in the field, uneven adoption 
of practices with lower-level evidence creates risks that beneficial practices will not 
disseminate completely or that practices that expose subsets of patients to undue toxicity or 
harm will not be identified and avoided. The registry maintained by the CIBMTR may be 
able, in some circumstances, to monitor emerging transplantation practices. Although some 
of these studies may be underpowered to draw definitive conclusions about effectiveness, 
potential safety signals may be identified that lead to larger studies. For example, 2 phase 2 
studies, published in early 2015, suggested a potential benefit for a thiotepa, busulfan, and 
cyclophosphamide conditioning regimen followed by autologous transplantation in the 
management of central nervous system lymphoma [11,12]. The extent to which this 
technique has disseminated into routine transplantation practice, and whether observed 
toxicities in a real-world setting are similar to or different than those reported in the studies, 
is not known. Depending on available resources for enhanced data collection, the CIBMTR 
might be able to investigate a question like this in relatively rapid fashion. Safety signals or 
triggers for further analysis after the initial investigation would need to be determined. At 
the same time, factors associated with faster or slower rates of innovation uptake could be 
identified to facilitate implementation of “best practices” as these are determined. It is likely 
that a group of individuals would need to be appointed to periodically determine which 
emerging technology questions are of the most urgent priority to the field to minimize 
reporting burden upon centers.
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Clinical Decision Support
The results of our hypothetical vignettes suggest that transplantation technique preferences 
vary among clinicians, but estimates of the efficacy of these practices may converge around 
cognitive anchors that may or may not correspond to published data. This is not surprising in 
a field where there are many possible permutations of patient-, disease-, and transplantation-
related variables for any given clinical scenario. Certain combinations of variables may be 
more or less familiar to clinicians based on personal experience. Further, clinicians may be 
challenged to readily identify published data that corresponds to a particular clinical 
scenario encountered in practice. To the extent that data do exist, patient-centered outcomes 
such as quality of life and functional status are often not included. These deficiencies may 
create barriers to achieving a balanced appraisal of the risks and benefits of a management 
approach that is being considered. Thus, there may be a role for electronic platforms that 
facilitate the spread of personal experience and published data throughout the transplantation 
community, such as the recently launched American Society for Blood and Marrow 
Transplantation Clinical Case Forum [13]. There may also be a role for entities such as the 
CIBMTR to develop point-of-care risk calculators that can guide clinical decision-making, 
similar to Adjuvant Online (https://adjuvantonline.com/), which is used for breast cancer 
[14,15]. These calculators could integrate known risk indices, such as the HCT-CI, and 
emerging risk factors as these are identified, so that clinician estimates of efficacy or toxicity 
would vary appropriately based on the literature, rather than converging around similar 
estimates for most scenarios as we observed in the vignettes. If the CIBMTR incorporates 
patient-reported outcomes into routine data collection, these risk calculators could become 
even more relevant for patient counseling [16-18]. Of note, the CIBMTR currently has an 
online survival calculator for allogeneic HCT, using the center-specific survival analysis 
model to generate estimates for 1-year overall survival based on a set of user-inputted 
individual patient characteristics. Calculators like this, as they become further developed and 
more widely available, may prove an invaluable resource for transplantation clinicians.
CONCLUSION
In our survey of HCT clinicians, we identified prevalent but uneven uptake of newer 
technologies in transplantation practice, variation among clinicians in transplantation 
preferences, and potential challenges in point of care risk/ benefit estimation in routine 
practice. These observations highlight the value of networks such as the BMT CTN 
dedicated to the conduct of prospective, controlled clinical trials; warrant further study to 
confirm these findings; and support approaches to facilitate advancements in transplantation 
outcomes throughout the community.
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Figure 1. 
Recommendations for various maintenance strategies after transplantation for patients in 
remission. FLT3 was the designation for the use of FLT inhibitors for FLT3 ITD+ acute 
myeloid leukemia patients in morphologic remission after allogeneic HCT; BCR/ABL+ for 
the use of tyrosine kinase inhibitor maintenance therapy for Philadelphia chromosome–
positive acute lymphoblastic leukemia patients in remission after allogeneic HCT; 
BCR/ABL− for the use of antibody-based maintenance therapy for Philadelphia 
chromosome–negative acute lymphoblastic leukemia patients in remission after allogeneic 
HCT; HMA for the use of hypomethylating agents for myelodysplastic syndrome or acute 
myeloid leukemia patients in remission after allogeneic HCT; DLBCL for the use of 
maintenance therapy such as rituximab, ibrutinib, or lenalidomide for DLBCL in remission 
after autologous HCT. HMA indicates hypomethylating agent; DLBCL, diffuse large B cell 
lymphoma.
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Figure 2. 
Responses to the use of newer medications in the initial management of graft-versus-host 
disease (GVHD), whether instead of corticosteroids (low-risk acute GVHD), in addition to 
corticosteroids (high-risk acute GVHD), or with or without corticosteroids (chronic GVHD). 
MSC indicates mesenchymal stem cells; PI, proteasome inhibitor.
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Figure 3. 
Common prognostic variables in highest volume centers (>100 allogeneic transplantations 
per year) for pretransplantation risk stratification. Participants could check as many tools as 
they wished. HCT-CI indicates HCT-related comorbidity index; DRI, Disease Risk Index; 
6MWD, 6-minute walk distance; PAM, Pretransplant Assessment of Mortality score; CGA, 
comprehensive geriatric assessment; VO2 peak, peak oxygen uptake; EBMT, European 
Group for Blood and Marrow Transplantation risk score.
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Figure 4. 
Breakdown of responses for vignette involving 45-year-old female with intermediate-risk 
AML (CN, FLT3/NPM1-) in remission after induction therapy with no comorbidities, 
matched sibling, performs all instrumental activities of daily living and continues to work. 
Allo indicates allogeneic; RIC, reduced-intensity; TRM, treatment-related mortality.
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Figure 5. 
Breakdown of responses for vignette involving 30-year-old male standard-risk BCR/ABL- 
B-ALL in first complete remission after “adult-like” induction with matched sibling and 
HCT-CI = 0. TBI indicates total body irradiation; allo, allogeneic.
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Table 1
Survey Respondents Self-Report of HCT Physician, HCT Center, and Patients
HCT Physician Characteristics n (%)
Practice setting
    Academic 262 (85.9%)
    Community 43 (14.1%)
Age
    30-40 yr 73 (24.8%)
    41-50 yr 90 (30.6%)
    51-60 yr 79 (26.9%)
    ≥ 60 yr 52 (17.7%)
Percent effort in clinical duties
    <20% 13 (4.3%)
    20%-39% 59 (19.3%)
    40%-59% 80 (26.2%)
    60%-79% 91 (29.8%)
    80%-100% 62 (20.3%)
Duration of practice as HCT physician
    ≤uryr 68 (23.2%)
    5-15 yr 83 (28.3%)
    15-25 yr 69 (23.6%)
    ≥9 yr 73 (24.9%)
Adult 190 (64.9%)
Pediatric 93 (31.7%)
Adult and pediatric 10 (3.4%)
HCT Center and Patient Characteristics n (%)
BMT CTN center status
    Core 164 (53.8%)
    Affiliate 108 (35.4%)
    Not a BMT CTN center 33 (10.8%)
Geographic location
    Mid-Atlantic 34 (11.2%)
    Midwest 85 (27.9%)
    Northeast 59 (19.3%)
    Pacific 42 (13.8%)
    Southeast 48 (15.7%)
    Southwest 37 (12.1%)
Center auto experience
    <20 65 (22.2%)
    20-50 66 (22.5%)
    50-100 58 (19.8%)
    >100 104 (35.5%)
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HCT Center and Patient Characteristics n (%)
Center allo experience
    <20 46 (15.7%)
    20-50 81 (27.7%)
    50-100 77 (26.3%)
    >100 89 (30.4%)
Allo indicates allogeneic.
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Table 2
Use of Additional Transplantation Strategies
Response Post Cy Donor NK cells CMV T Cells DEXA Allo
No, do not recommend 101 of 267 (37.8%) 243 of 267 (91.0%) 187 of 266 (70.3%) 190 of 266 (71.4%)
Yes, on/off trials and within trial 166 of 267 (62.2%) 24 of 267 (9.0%) 79 of 266 (29.7%) 76 of 266 (28.6%)
Post Cy indicates post-transplantation cyclophosphamide for GVHD prophylaxis; Donor NK cells, haploidentical donor natural killer cells for post-
transplantation relapse prevention; CMV T cells, cytomegalovirus-specific T cells for refractory cytomegalovirus infection; DEXA allo, screening 
and prevention strategies for post-transplantation bone density loss.
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Table 3
Use of Selected Transplantation Techniques and Maintenance Strategies
Center Size
Technologies <20 20-50 50-100 >100
FLT3 21 of 39 (53.9%) 54 of 78 (69.2%) 43 of 71 (60.6%) 68 of 81 (84.0%)
DLBCL 9 of 65 (13.9%) 10 of 61 (16.4%) 8 of 56 (14.3%) 20 of 101 (19.8%)
IL-2 1 of 37 (2.7%) 7 of 78 (9.0%) 8 of 70 (11.4%) 17 of 81 (21.0%)
Auto for MS 6 of 65 (9.2%) 10 of 61 (16.4%) 9 of 56 (16.1%) 36 of 101 (35.6%)
Post-Cy 9 of 38 (23.7%) 38 of 78 (48.7%) 24 of 70 (34.3%) 41 of 81 (50.6%)
Donor NKs 2 of 78 (2.6%) 4 of 70 (5.7%) 1 of 38 (2.6%) 17 of 81 (21.0%)
The number of allogeneic transplantations performed each year was used as a proxy for center size.
Data provided reflect the responses “Yes, including patients who are on and off clinical trials” and “Yes, only within the context of a clinical trial.”
FLT3 indicates use of FLT inhibitors for FLT3 ITD+ AML patients in morphologic remission after allogeneic HCT; DLBCL, use of maintenance 
therapy such as rituximab, ibrutinib, or lenalidomide for diffuse large B cell lymphoma patients in remission after autologous HCT; IL-2 for 
patients with chronic GVHD (with or without steroids); Auto for MS, autologous transplantation for multiple sclerosis.
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Table 4
Use of Prognostic Variables More Common in Higher Volume Centers for Pretransplantation Risk 
Stratification
Center Size
Prognostic Variable <20 20-50 50-100 >100
CGA 1 of 42 (2.4%) 3 of 80 (3.8%) 9 of 71 (12.7%) 12 of 87 (13.9%)
PAM 3 of 42 (7.1%) 6 of 80 (7.5%) 3 of 71 (4.2%) 12 of 87 (13.8%)
HCT-CI 14 of 42 (33.3%) 50 of 80 (62.5%) 55 of 71 (77.5%) 77 of 87 (88.5%)
DRI 4 of 42 (9.5%) 17 of 80 (21.3%) 17 of 71 (23.9%) 32 of 87 (36.8%)
EBMT 4 of 42 (9.5%) 4 of 80 (5.0%) 6 of 71 (8.5%) 2 of 87 (2.3%)
6MWD 3 of 42 (7.1%) 5 of 80 (6.3%) 10 of 71 (14.1%) 16 of 87 (18.4%)
VO2 Peak 1 of 42 (2.4%) 2 of 80 (2.5%) 3 of 71 (4.2%) 2 of 87 (2.3%)
The number of allogeneic transplantations performed each year was used as a proxy for center size.
CGA indicates comprehensive geriatric assessment; PAM, Pre-transplant Assessment of Mortality score; DRI, Disease Risk Index; EBMT, 
European Group for Blood and Marrow Transplantation risk score; 6MWD, 6-minute walk distance; VO2 peak, peak oxygen uptake.
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